Zydus Lifesciences has launched its Semaglutide Injection in India under the brand names SEMAGLYN, MASHEMA, and ALTERME, following patent expiry. The drug is offered with an innovative, reusable multi-dose pen device, designed to improve patient adherence and convenience while lowering overall therapy costs. The treatment, indicated for Type 2 Diabetes Mellitus and Obesity, will be available at an estimated monthly cost of Rs. 2,200.
Zydus Introduces Semaglutide Injection in India
Zydus Lifesciences Limited announced on March 21, 2026, the launch of its Semaglutide Injection in the Indian market. The drug is now available under three proprietary brand names: SEMAGLYN™, MASHEMA™, and ALTERME™, capitalizing on the recent patent expiry in the country. The launch addresses treatments for both Type 2 Diabetes Mellitus and Obesity indications, having previously secured approval from the Drug Controller General of India (DCGI).
Innovative Multi-Dose Pen Technology
A key differentiator of this launch is the introduction of an innovative, reusable multi-dose novel pen device. Unlike current options that necessitate patients purchase multiple single-dose pens for dosage titration, Zydus’s offering allows clinicians and patients to conveniently select and administer different dose strengths from a single pen. This advancement is expected to significantly improve patient adherence and enhance convenience.
Product Availability and Cost
- The Semaglutide injection will be supplied in a 15mg/3ml cartridge.
- Manufacturing will take place at Zydus Biotech Park, Ahmedabad.
- The estimated average monthly cost for the treatment is projected to be approximately Rs. 2,200.
Addressing India’s Growing Health Challenges
The announcement highlights the severity of diabetes and obesity in India, positioning GLP-1 based treatments as crucial interventions. Citing data from the International Diabetes Federation, the document notes that 8.9 crore adults in India currently live with diabetes, representing 10.5 per cent of the adult population. Furthermore, obesity rates are rising sharply, with prevalence among adults increasing by 91 per cent in women and 146 per cent in men over recent years, indicating a widening public health crisis.
About Zydus Lifesciences Limited
Zydus Lifesciences Ltd. is described as an innovative, global lifesciences company driven by the purpose of empowering people to live healthier lives. The group employs over 29,000 people worldwide, including 1,500 scientists engaged in Research & Development, focusing on developing, manufacturing, and marketing a wide array of healthcare therapies.
Source: BSE
